MARKET

DCTH

DCTH

Delcath Systems Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

9.85
+0.11
+1.13%
After Hours: 9.85 0 0.00% 16:00 09/24 EDT
OPEN
9.58
PREV CLOSE
9.74
HIGH
9.90
LOW
9.54
VOLUME
19.10K
TURNOVER
--
52 WEEK HIGH
25.18
52 WEEK LOW
8.28
MARKET CAP
72.46M
P/E (TTM)
-2.1469
1D
5D
1M
3M
1Y
5Y
Delcath Systems to Present at Upcoming Virtual Investor Conferences
NEW YORK, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will participate in three upcoming conferences...
GlobeNewswire · 09/02 13:00
Clinicaltrials.gov Site Shows Delcath Systems Study 'An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma' Available
https://clinicaltrials.gov/ct2/show/NCT05022901
Benzinga · 08/26 13:30
Delcath Systems, Inc. (DCTH) Reports Q2 Loss, Tops Revenue Estimates
Zacks.com · 08/10 12:45
Delcath Systems: Q2 Earnings Insights
  Shares of Delcath Systems (NASDAQ:DCTH) fell 13.6% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 49.47% over the past year to ($0.96), which beat the estimate of ($0.99).
Benzinga · 08/10 11:54
BRIEF-Delcath Systems Announces Q2 Results
reuters.com · 08/10 11:46
-- Earnings Flash (DCTH) DELCATH SYSTEMS Posts Q2 Loss $-0.96
MT Newswires · 08/10 07:40
Earnings Preview For Delcath Systems
Delcath Systems (NASDAQ:DCTH) announces its next round of earnings this Tuesday, August 10. Here is Benzinga's everything-that-matters guide for this Tuesday's Q2 earnings announcement.
Benzinga · 08/09 15:35
BRIEF-Delcath Systems Secures Up To A $20 Mln Debt Facility With Avenue Venture Opportunities Fund LP
reuters.com · 08/09 11:31
More
Forecast
Actual (M USD)
Estimate (M USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of DCTH. Analyze the recent business situations of Delcath Systems Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average DCTH stock price target is 22.75 with a high estimate of 25.00 and a low estimate of 19.00.
EPS
Institutional Holdings
Institutions: 37
Institutional Holdings: 1.59M
% Owned: 21.65%
Shares Outstanding: 7.36M
TypeInstitutionsShares
Increased
6
132.25K
New
9
111.61K
Decreased
2
23.47K
Sold Out
8
152.17K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
-0.61%
Healthcare Equipment & Supplies
-0.42%
Key Executives
Non-Executive Chairman/Independent Director
Roger Stoll
Chief Executive Officer/Director
Gerard Michel
Chief Operating Officer/Executive Vice President
John Purpura
Chief Accounting Officer
Christine Padula
Independent Director
Gilad Aharon
Independent Director
Elizabeth Czerepak
Independent Director
Steven Salamon
Independent Director
John Sylvester
No Data
  • All
  • Financials
  • Insiders
More
About DCTH
Delcath Systems, Inc. is an oncology company. The Company is focused on the treatment of primary and metastatic liver cancers. The Company is a specialty pharmaceutical and medical device company developing its products. The Company's lead product candidate is HEPZATO KIT (melphalan hydrochloride for injection/hepatic delivery system) is a drug/device combination product. HEPZATO is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The Company's focus is on the execution of the clinical development program (CDP) in ocular melanoma liver metastases (mOM), intrahepatic cholangiocarncinoma (ICC), hepatocellular carcinoma (HCC or primary liver) and other cancers that are metastatic to the liver.

Webull offers kinds of Delcath Systems Inc stock information, including NASDAQ:DCTH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DCTH stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading DCTH stock methods without spending real money on the virtual paper trading platform.